You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Basmisanil


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Basmisanil?

Basmisanil is an investigational drug.

There have been 4 clinical trials for Basmisanil. The most recent clinical trial was a Phase 2 trial, which was initiated on March 30th 2022.

The most common disease conditions in clinical trials are Down Syndrome, Syndrome, and Schizophrenia. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].

There are ten US patents protecting this investigational drug and one hundred and thirty-three international patents.

Recent Clinical Trials for Basmisanil
TitleSponsorPhase
A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children With Dup15q SyndromeHoffmann-La RochePhase 2
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic StrokeHoffmann-La RochePhase 2
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With AntipsychoticsHoffmann-La RochePhase 2

See all Basmisanil clinical trials

Clinical Trial Summary for Basmisanil

Top disease conditions for Basmisanil
trials000001111111Down SyndromeSyndromeSchizophreniaCognitive Dysfunction[disabled in preview]
Top clinical trial sponsors for Basmisanil
trials011223344Hoffmann-La Roche[disabled in preview]

See all Basmisanil clinical trials

US Patents for Basmisanil

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Basmisanil ⤷  Subscribe Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Subscribe
Basmisanil ⤷  Subscribe Isoxazolo-pyridine derivatives Hoffmann-La Roche Inc (Nutley, NJ) ⤷  Subscribe
Basmisanil ⤷  Subscribe Process for the preparation of isoxazolyl-methoxy nicotinic acids Hoffman-La Roche Inc. (Nutley, NJ) ⤷  Subscribe
Basmisanil ⤷  Subscribe Solid forms Hoffmann-La Roche Inc. (Nutley, NJ) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 4 of 4 entries

International Patents for Basmisanil

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Basmisanil Australia AU2017261372 2036-05-05 ⤷  Subscribe
Basmisanil Canada CA3023278 2036-05-05 ⤷  Subscribe
Basmisanil China CN107847398 2036-05-05 ⤷  Subscribe
Basmisanil European Patent Office EP3452003 2036-05-05 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 4 of 4 entries

Development Update and Market Projection for Basmisanil (RG1662)

Introduction

Basmisanil, also known as RG1662, is a promising drug candidate developed by Hoffmann-La Roche. It is a highly selective negative allosteric modulator of the α5 subunit-containing GABA_A receptors. Here, we will delve into the current development status, clinical trials, and market projections for this drug.

Pharmacological Profile

Basmisanil has shown a unique pharmacological and safety profile, making it a potential therapeutic agent for various neurological and psychiatric conditions. It produces rapid and sustained antidepressant-like responses in preclinical studies, particularly in male mice, and demonstrates effective blood-brain barrier penetration[1][4].

Clinical Trials for Cognitive Impairment Associated with Schizophrenia

One of the primary focuses of basmisanil's clinical development has been its potential to treat cognitive impairment associated with schizophrenia. The drug was in Phase 2 clinical trials for this indication. These trials aimed to evaluate the safety and efficacy of basmisanil in participants treated with antipsychotics. Although the trials were recruiting and had shown promising baseline data, they were ultimately terminated due to a sponsor decision, not related to safety or tolerability[1][4].

Clinical Trials for Dup15q Syndrome

In addition to its application in schizophrenia, basmisanil was also being investigated for the treatment of Dup15q syndrome, a genetic disorder characterized by intellectual disability and various physical and behavioral abnormalities. A Phase 2 study was conducted to evaluate the safety and efficacy of basmisanil in children aged 2-14 years with this condition. However, this study was also terminated due to a sponsor decision and not related to safety or tolerability[1].

Termination of Trials

Despite the promising preclinical and early clinical data, Roche decided to terminate the Phase 2 trials for both cognitive impairment associated with schizophrenia and Dup15q syndrome. This decision was not based on safety or tolerability issues but rather on strategic considerations by the sponsor[1][5].

Market Implications

The termination of these trials, while not due to safety concerns, has significant implications for the market potential of basmisanil. The drug had been seen as a novel therapeutic strategy for conditions associated with cognitive impairment, particularly in the context of schizophrenia and Dup15q syndrome.

Global Drug Discovery Market

The global drug discovery market is projected to grow significantly, with a CAGR of 14.90% from 2021 to 2033, reaching USD 62.10 billion by 2033. North America and Europe are expected to be key drivers of this growth, with advanced research infrastructure and substantial investments in biotechnology and R&D[3].

Competitive Landscape

In the context of this growing market, basmisanil's unique mechanism of action as a negative allosteric modulator of α5-GABA_A receptors had positioned it as a potential breakthrough therapy. However, its removal from active development reduces the competitive pressure in the niche markets it was targeting.

Future Prospects

Although the current trials have been terminated, the data collected so far suggest that basmisanil has a promising pharmacological and safety profile. This could pave the way for future reevaluation or repurposing of the drug in other therapeutic areas.

Potential Repurposing

Given its unique pharmacological properties, basmisanil could be repurposed for other conditions associated with GABA_A receptor dysfunction. This would require new clinical trials and regulatory approvals but could offer a second chance for the drug to enter the market.

Key Takeaways

  • Pharmacological Profile: Basmisanil is a highly selective negative allosteric modulator of α5-GABA_A receptors with rapid and sustained antidepressant-like effects.
  • Clinical Trials: Trials for cognitive impairment associated with schizophrenia and Dup15q syndrome were terminated due to sponsor decisions, not safety or tolerability issues.
  • Market Implications: The termination affects its market potential, but the drug's unique profile keeps it a candidate for future repurposing.
  • Global Market: The drug discovery market is growing, with North America and Europe leading the way, but basmisanil's current status reduces its immediate impact.

FAQs

What is Basmisanil?

Basmisanil, or RG1662, is a drug candidate developed by Hoffmann-La Roche. It is a negative allosteric modulator of the α5 subunit-containing GABA_A receptors.

What conditions was Basmisanil being tested for?

Basmisanil was being tested for cognitive impairment associated with schizophrenia and Dup15q syndrome.

Why were the clinical trials for Basmisanil terminated?

The clinical trials were terminated due to a sponsor decision, not related to safety or tolerability issues.

What is the current market outlook for Basmisanil?

Given the termination of its current trials, the immediate market outlook for basmisanil is limited. However, its unique pharmacological profile leaves room for potential future repurposing.

Is Basmisanil still a promising drug candidate?

Yes, despite the termination of current trials, basmisanil's pharmacological and safety profile suggests it remains a promising candidate for future therapeutic applications.

What are the potential future applications of Basmisanil?

Basmisanil could be repurposed for other conditions associated with GABA_A receptor dysfunction, pending new clinical trials and regulatory approvals.

Sources

  1. LARVOL Sigma: Basmisanil (RG1662) News.
  2. Roche Half Year 2023 Results: Roche Half Year 2023 Results.
  3. Straits Research: Drug Discovery Market Size, Share and Trends by 2033.
  4. LARVOL DELTA: Preclinical and Early Clinical Pharmacological Profile of Basmisanil.
  5. Fierce Biotech: Roche culls key phase 3 drug trials, including a cancer med and an autism breakthrough therapy.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.